Clinical Trial Update: Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating EG1206A (EirGenix's pertuzumab) versus EU-sourced Perjeta in HER2-positive hormone receptor-negative early breast cancer has been wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• EG1206A (pertuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: EirGenix, Inc. | Conditions: Early Breast Cancer | Phase 3 | Status: WITHDRAWN